ALB and chronic kidney disease: The first was the DAPA‐CKD trial with dapagliflozin in 4304 patients with an eGFR between 25 and 75 ml/min/1.73 m2, and a urinary albumin‐to‐creatinine ratio between 200 and 5000 mg/g.12